Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Gains from Investment Securities (2016 - 2025)

STRATA Skin Sciences' Gains from Investment Securities history spans 13 years, with the latest figure at $34000.0 for Q2 2025.

  • For Q2 2025, Gains from Investment Securities rose 103.41% year-over-year to $34000.0; the TTM value through Sep 2025 reached -$1.0 million, down 197.34%, while the annual FY2024 figure was $521726.0, 3378.17% up from the prior year.
  • Gains from Investment Securities for Q2 2025 was $34000.0 at STRATA Skin Sciences, up from -$34000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.9 million in Q1 2021 and bottomed at -$1.0 million in Q4 2024.
  • The 5-year median for Gains from Investment Securities is -$13500.0 (2021), against an average of $864684.8.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 36549.88% in 2021 before it plummeted 4050.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $73000.0 in 2021, then tumbled by 123.29% to -$17000.0 in 2022, then soared by 552.94% to $77000.0 in 2023, then crashed by 1432.47% to -$1.0 million in 2024, then skyrocketed by 103.31% to $34000.0 in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Gains from Investment Securities are $34000.0 (Q2 2025), -$34000.0 (Q1 2025), and -$1.0 million (Q4 2024).